MDS patients achieve access to vital new treatment option

NICE – National Institute for Health and Clinical Excellence – finally recommend azacitidine is available through the NHS for intermediate 2 and high-risk MDS, AML and CMML for England and Wales. The MDS UK Patient Support Group, which has been in consultation with NICE during the approval process and campaigned on behalf and in conjunction with MDS patients across the UK for almost 2 years, welcomes this announcement.

Full details in the news page.

Read full story

NICE survey – please take part

NICE, the National Institute for Health and Clinical Excellence is running a survey about their work amongst the general public – and health professionals. Please do take part – even if you are not familiar with all aspects of their activities.

Read full story
Free donations by shopping